EMA explains when to use active controls in clinical trials
This article was originally published in SRA
Executive Summary
The European Medicines Agency has issued a draft reflection paper explaining when drug companies should make use of active control in clinical trials. The scope of the paper is restricted to therapeutic areas where the use of a placebo is deemed ethical and one or more established medicines are available1,2.
You may also be interested in...
COVID-19 Vaccine Dosing: Pharma Says Follow The Science As It Gathers Data
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
India Permits Sale Of Some Devices Beyond Licensing Deadline
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Australia Considers Redefining Central Circulatory System To Align With EU
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: